Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
These names fell hard post earnings and look to have more downside action in store.
A high dividend yield can look like a ticket to lasting retirement income, until the cut arrives. Before rushing into a high-yield name, ask yourself three questions.
Here’s how to take advantage of down times in the market, to expect cycles of bullish and bearish periods, and become a better trader.
Let’s scan through the headlines for the stories of the week that speak to our Pro Portfolio holdings.
We locked in massive gains on two positions and added to two beaten-down holdings.
Good news from Trulieve ($TRLV) after the close.
Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Position: Long TRLV (S)
After-Hours % Advancers

After-Hours % Decliners

Position: None
Closing Volume
– NYSE volume 11% below its one-month average
– NASDAQ volume flat to its one-month average
– VIX index: down 2.54% to 18.41
Breadth

S&P 500 Sectors

% Movers

Nasdaq 100 Heat Map

Closing S&P 500 Heat Map

Position: None